BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genelex Corporation Receives First Patent on Business Methods for Pharmacogenetics


8/1/2012 10:25:52 AM

SEATTLE, Aug. 1, 2012 /PRNewswire/ -- Genelex Corporation today announced the acceptance of US Patent 8,099,298 titled, "Genetic Data Analysis and Database Tools." Genelex's patent, filed in early 2007, covers a variety of innovations for genetic analysis and interpretation, personalized prescribing, electronic medical records processing, and online reimbursement.

Notably covered are the algorithms which analyze and interpret patient specific pharmacogenetic and pharmacological information. These algorithms provide actionable insight into drug-drug and drug-gene interactions and are the backbone of comprehensive medication management reports and recommendations. These sophisticated software tools enable selection at the point-of-care of the safest and most effective drug and dose combinations for patients.

"The USPTO's issuance of this patent further demonstrates our leadership position in the rapidly growing Pharmacogenetics marketplace," stated Howard Coleman, Chief Executive Officer of Genelex. "Everyday prescribers call on us to help prevent and reduce adverse drug events improving and saving patient's lives and saving healthcare dollars."

Genelex has additional patents pending and continues to strengthen its Pharmacogenetics intellectual property and business model leadership.

About Genelex
Headquartered in Seattle, Genelex provides advanced decision support tools and genetic tests that help healthcare providers choose the safest, most effective medication regimens for their patients. Our personalized prescribing system takes the guesswork out of medication management and can reduce the incidence of adverse drug events, saving lives and healthcare dollars. For more information, please visit www.genelex.com.

SOURCE Genelex Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES